Dr Sophie Zaloumis is a senior biostatistician at the Melbourne School of Population and Global Health, The University of Melbourne, and previously was awarded an Australian Research Council Discovery Early Career Researcher Award (2017-2019). Her research interests are Bayesian inference for high-dimensional non-linear models, pharmacokinetic-pharmacodynamic modelling of antimalarial drugs and machine learning methods.Related Projects
Related Publications
- A dynamic stress model explains the delayed drug effect in artemisinin treatment of Plasmodium falciparum
- A mechanistic model quantifies artemisinin-induced parasite growth retardation in blood-stage Plasmodium falciparum infection
- Altered temporal response of malaria parasites determines differential sensitivity to artemisinin
- Anti-Gametocyte Antigen Humoral Immunity and Gametocytemia During Treatment of Uncomplicated Falciparum Malaria: A Multi-National Study
- Community-based molecular and serological surveillance of subclinical malaria in Myanmar
- Comparison of Antibody Responses and Parasite Clearance in Artemisinin Therapeutic Efficacy Studies in the Democratic Republic of Congo and Asia
- Effect of adherence to primaquine on the risk of Plasmodium vivax recurrence: a WorldWide Antimalarial Resistance Network systematic review and individual patient data meta-analysis
- How to use learning curves to evaluate the sample size for malaria prediction models developed using machine learning algorithms
- In silico investigation of the decline in clinical efficacy of artemisinin combination therapies due to increasing artemisinin and partner drug resistance
- Investigating the efficacy of triple artemisinin-based combination therapies (TACTs) for treating Plasmodium falciparum malaria patients using mathematical modelling
- Making the most of clinical data: reviewing the role of pharmacokinetic-pharmacodynamic models of anti-malarial drugs
- Modeling the dynamics of Plasmodium falciparum gametocytes in humans during malaria infection
- Seeking an optimal dosing regimen for OZ439/DSM265 combination therapy for treating uncomplicated falciparum malaria